Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

ASTX 295

Next Previous
Search
Drug Profile

ASTX 295

Alternative Names: ASTX-295

Latest Information Update: 28 Feb 2025

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Northern Institute for Cancer Research
  • Developer Astex Pharmaceuticals; Northern Institute for Cancer Research
  • Class Antineoplastics; Isoindoles; Small molecules
  • Mechanism of Action Proto-oncogene protein c-mdm2 inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase I/II Solid tumours
  • No development reported Acute myeloid leukaemia

Most Recent Events

  • 07 Dec 2024 Pharmacodynamics data from a preclinical trial in Lymphoid Malignancies presented at the 66th American Society of Hematology Annual Meeting and Exposition (ASH-2024)
  • 23 Oct 2024 Pharmacodynamics and pharmacokinetics data from the preclinical trials in Solid tumours presented at the 36th EORTC-NCI-AACR Symposium on molecular targets and cancer therapeutics (EORTC-NCI-AACR-2024)
  • 15 Aug 2024 Taiho Oncology terminates phase-I/II clinical trials in Solid tumours (Inoperable/Unresectable, Late-stage disease, Metastatic disease, Second-line therapy or greater) in Spain, Italy, France, Germany, USA (PO) due to Sponsor's decision (NCT03975387) (EudraCT2021-005033-16)

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top